



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 March 2017
EMA/CAT/195978/2017
Inspections, Human Medicines Pharmacovigilance and Committees Division

CAT monthly report of application procedures, guidelines and related documents on advanced therapies

March 2017 meeting

The Committee for Advanced Therapies (CAT) held its 91st CAT meeting on 15 – 17 March 2017.

The CAT Monthly Report includes statistical data on CAT scientific recommendations on Advanced Therapy Medicinal Product (ATMP) classification, certifications, initial evaluations, CAT contributions to Scientific Advice and Paediatric Investigation Plans, as well as variations, line extensions, renewals.

CAT elected a new vice-chair

The CAT elected Ilona Reischl as its new vice-chair for a three-year mandate.

Ilona Reischl, who is Head of Clinical Trials at the Austrian Medicines and Medical Devices Agency (BASG), has been with the CAT since its creation in 2009, as the Austrian member or alternate.

Scientific recommendation on advanced therapy product classification

Further to consultation with the European Commission, the CAT finalised one scientific recommendation on the classification of advanced therapy medicinal products.

The following product was classified as a somatic cell therapy medicinal product:

- Autologous tumour-infiltration lymphocytes intended for the treatment of metastatic melanoma.

Organisational matters

- CAT finalised the Question and Answer document on minimally manipulated cell-based ATMPs. The document is scheduled for adoption at the April 2017 CAT meeting.
- CAT finalised the programme of the CAT Strategy Review and Learning meeting that will take place on 1 – 2 June 2017 in Malta under the auspices of the Maltese Presidency of the Council of the European Union.



Overview of product-related activities

The Committee discussed ongoing evaluation procedures for ATMPs and other related procedures as summarised in the following tables:

Initial Evaluation of Marketing Authorisation Applications (MAA) for ATMP										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Submitted MAAs	3	1	2	3	2	2	1	1	0	15
Positive draft Opinion	1	0	1 ⁱⁱ	1 ⁱⁱ	2	1	1	2	0	9*
Negative draft opinions	1 ⁱ	0	1 ⁱⁱ	0	0	0	2 ⁱⁱⁱ	0	0	4
Withdrawals	1	1 ⁱ	0	0	2	0	0	0	0	4
Ongoing MAAs										2

* Corresponding to 8 ATMPs

ⁱ Same product (Cerepro)

ⁱⁱ Same product (Glybera)

ⁱⁱⁱ CAT adopted two negative draft opinions for the same product (Heparesc)

Variations (Type II) for authorised ATMP										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Positive Opinion	0	0	1	1	9	4	3	6	0	24

Scientific recommendation on advanced therapy classification										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Submitted	22	19	12	22	20	28	61	60	14	258
Adopted	12	27	12	16	23	29	31	87	8	245

Certification of quality and non-clinical data for small and medium-sized enterprises developing ATMPs										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Submitted	1	0	0	1	3	1	1	2	1	10
Adopted	0	1	0	1	1	2	1	1	2	9

Scientific advice procedure for ATMPs										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Number of procedures	17	19	21	19	23	33	39	46	14	231

Paediatric Investigation Plans (PIP) for ATMPs										
	2009	2010	2011	2012	2013	2014	2015	2016	2017	Total
Number of procedures	3	4	4	8	5	4	3	5	1	37

Prime Eligibility for ATMPs										
	2016	2017								Total
Discussed	22	6								28
Granted	8	3								11

Upcoming meetings following the March 2017 CAT meeting

The 92nd meeting of the CAT will be held on 10 – 12 April 2017.

NOTE:

1. This Monthly Report, the Agenda of this meeting, the Minutes of the previous CAT meeting and other documents can be found on the internet at the following location: [European Medicines Agency - Committee meeting reports - CAT: Committee meeting reports](#)
2. Specific information related to ATMPs and the activities of the CAT (role, responsibilities and composition) can be found at: [European Medicines Agency - CAT - Committee for Advanced Therapies \(CAT\)](#)

Thorsten Olski

Head of Scientific Committees Secretariat

Tel.: (+44-20) 3660 8449

Fax: (+44-20) 3660 5520

AdvancedTherapies@ema.europa.eu